Alladapt Immunotherapeutics is a clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergies. Their lead product candidate, ADP101, is designed as a multi-food oral immunotherapy to treat allergies to various common food allergens simultaneously.